NAMS — NEWAMSTERDAM PHARMA COMPANY

Ownership history in First Turn Management, LLC  ·  3 quarters on record

This page tracks every 13F SEC filing in which First Turn Management, LLC reported a position in NEWAMSTERDAM PHARMA COMPANY (NAMS). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
3.58% (2025 Q4)
Avg. % of fund
2.8%
First filed
2025 Q2
Last filed
2025 Q4
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 893,473 +176,502 +24.6% 3.58% $31.3M $35.08
2025 Q3 ADDED 716,971 +195,874 +37.6% 3.06% $20.4M $28.44
2025 Q2 INITIATED 521,097 — — 1.76% $9.4M $18.11
% of Fund (quarterly)    NAMS price (monthly, adj. close)

Other funds also holding NAMS

As of 2025 Q4 — sorted by position size

FCPM III SERVICES B.V. 42.3% Bain Capital Life Sciences Investors, LLC 3Y 7Y 19.63% Frazier Life Sciences Management, L.P. 3Y 15.96% Medicxi Ventures Management (Jersey) Ltd 3Y 12.06% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 3.43% Decheng Capital LLC 2.79% Artia Global Partners LP 3Y 2.5% Duquesne Family Office LLC 3Y 7Y 2.4% Atle Fund Management AB 3Y 7Y 2.21% DEERFIELD MANAGEMENT COMPANY, L.P. 3Y 7Y 1.87%
← Back to First Turn Management, LLC Holdings